PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS, COMPRISING, AS ACTIVE INGREDIENT, STEM CELLS HAVING EXPRESSION OF SPECIFIC GENES INCREASED OR DECREASED THEREIN
The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis, the composition comprising, as an active ingredient, human nasal inferior turbinate-derived stem cells in which the expression of specific genes is increased or decreased. The human nasal inferior turbinate-derived stem cells exhibiting a therapeutic effect on arthritis were identified to specifically have an increased expression level of HAS2, CXCL1, or KRTAP1-5 gene or a decreased expression level of GSTT2B or C4B gene. Thus, by taking advantage of this feature, only stem cells that have a therapeutic effect on arthritis can be selected for use in treating rheumatoid arthritis, with the expectation of enhancing the therapeutic effect. Furthermore, it is expected that a method for selecting stem cells useful as a therapeutic agent for rheumatoid arthritis can be provided..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 21. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KIM SUNG WON [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-21, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 |
|---|
| Patentnummer: |
US2023405051 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018904289 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018904289 | ||
| 003 | DE-627 | ||
| 005 | 20240126102616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240105s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018904289 | ||
| 035 | |a (EPA)US2023405051 | ||
| 035 | |a (EPA)81290978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KIM SUNG WON |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS, COMPRISING, AS ACTIVE INGREDIENT, STEM CELLS HAVING EXPRESSION OF SPECIFIC GENES INCREASED OR DECREASED THEREIN |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-21, Last update posted on www.tib.eu: 2024-01-23, Last updated: 2024-01-26 | ||
| 520 | |a The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis, the composition comprising, as an active ingredient, human nasal inferior turbinate-derived stem cells in which the expression of specific genes is increased or decreased. The human nasal inferior turbinate-derived stem cells exhibiting a therapeutic effect on arthritis were identified to specifically have an increased expression level of HAS2, CXCL1, or KRTAP1-5 gene or a decreased expression level of GSTT2B or C4B gene. Thus, by taking advantage of this feature, only stem cells that have a therapeutic effect on arthritis can be selected for use in treating rheumatoid arthritis, with the expectation of enhancing the therapeutic effect. Furthermore, it is expected that a method for selecting stem cells useful as a therapeutic agent for rheumatoid arthritis can be provided. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KWOK SEUNG KI |4 aut | |
| 700 | 0 | |a LEE JAESEON |4 aut | |
| 700 | 0 | |a JANG SE GWANG |4 aut | |
| 700 | 0 | |a LIM JUNG YEON |4 aut | |
| 700 | 0 | |a PARK SUN HWA |4 aut | |
| 700 | 0 | |a CHUN JUNG HO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 21. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81290978/publication/US2023405051A1?q=US2023405051 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 21 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 12 | ||